Pediatric Clinical Trials
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
Mantle cell lymphoma (MCL) is a sub-type of non-Hodgkin's lymphoma (NHL) which is generally considered incurable with current therapy. Participants will receive an autologous vaccine against their individual lymphoma after undergoing stem cell transplantation. This vaccination may prolong the time which patients will stay in remission from their disease.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Rituximab
- biological: CpG-MCL vaccine
- procedure: Vaccine-primed T-cells
- biological: PF-3512676
- procedure: Autologous hematopoietic stem cell transplant (HSCT)
- drug: Standard induction chemotherapy
- drug: Cyclophosphamide
- drug: Filgrastim
Eligibility
INCLUSION CRITERIA
- Newly-diagnosed with mantle cell lymphoma (MCL) with accessible disease site for
excisional biopsy, OR have sufficient peripheral blood tumor to leukapherese ≥ 1.5 x
10e9 lymphoma cells in a single session
- Medically appropriate by standard clinical criteria to receive rituximab and standard
induction chemotherapy and high-dose chemotherapy with autologous hematopoietic cell
transplant (AHCT)
- HIV-negative
- Eastern Cooperative Oncology Group (ECOG) Performance Status, OR Karnofsky performance
scale 50 to 100%
- Capable of providing informed consent
EXCLUSION CRITERIA
- Currently receiving immunosuppressive medications
- Severe psychological or medical illness
- Pregnant or lactating
- Unable to safely complete the study, at the discretion of the principal investigator
Ages Eligible for Study
21 Years - 70 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061
Not Recruiting